Loading
Life sciences · Journal article
Cancers · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality among cancer survivors. Contemporary cardio-oncology frameworks emphasize baseline cardiovascular risk assessment before potentially cardiotoxic cancer therapies. Historical real world implementation of baseline electrocardiography (ECG), however, remains incompletely characterized. The objective of this study was to characterize historical baseline ECG ascertainment before cancer diagnosis and examine its association with documented cardiovascular diagnosis patterns in cancer survivors. Methods: We conducted a retrospective observational cohort study of 4592 adult cancer survivors within the Froedtert & Medical College of Wisconsin health system from 2000 to 2020. The analytic cohort was derived from a previously established longitudinal cancer survivor resource integrating demographic and cardiovascular clinical data, cancer treatment exposures, multimodality cardiac function ascertainment, and linked clinical, radiation oncology, and cancer registry information. Cardiac function ascertainment from an available cardiovascular imaging modality within three years before cancer diagnosis was one component of the analytic cohort definition. Patients were stratified by ascertainment of a 12-lead ECG within the same pre-diagnostic interval. Cardiovascular diagnoses documented before and after cancer diagnosis were characterized separately. For the newly documented diagnosis analyses, each cardiovascular outcome was evaluated among participants without a prior diagnosis of that same condition before cancer diagnosis. A multivariable logistic regression model evaluated the association between baseline ECG ascertainment and newly documented overall CVD diagnosis (including HF, AFIB, CAD, and stroke) while adjusting for age, sex, race, comorbidity count, and treatment count. Results: Among 4592 individuals, 3726 (81%) had a baseline ECG. ECG ascertainment was associated with older age and greater pre-existing cardiovascular and cardiometabolic burden. The available follow up distributions were similar between patients without and with baseline ECG ascertainment (748 [Q1 258, Q3 1781] vs. 767 [Q1 219, Q3 1822] days; p > 0.9). In multivariable analysis, baseline ECG ascertainment was associated with lower odds of a newly documented overall CVD diagnosis (OR 0.38, 95% CI 0.31–0.46); this odds ratio represents an association rather than a time-specific risk or protective effect. Conclusions: Baseline ECGs were commonly ascertainable within this longitudinal cancer survivor cohort and identified groups with different pre-existing cardiovascular burden and subsequent cardiovascular diagnosis patterns. These findings provide a historical benchmark for cardiovascular assessment in cancer care and support prospective patient-level studies integrating ECG findings with clinical and oncologic risk factors to refine cardiovascular surveillance strategies across cancer survivorship.